GlassScriptPhysician profile
Arthur C Stowe
NPI 1376682856
$2,578.38
in general payments reported to CMS, 2019-2025
23 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $581 · 2021: $263 · 2022: $266 · 2023: $407 · 2024: $272 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $951.72 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $285.12 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $248.84 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $214.58 | 2020-2021 | |
| Boston Scientific Corporation | $166.47 | 2023-2024 | Exalt Model D, Spyglass |
| Gilead Sciences, INC. | $150.69 | 2019-2021 | |
| Celgene Corporation | $76.85 | 2022-2023 | Zeposia |
| Novo Nordisk INC | $73.83 | 2019-2025 | Wegovy |
| Abbvie INC. | $69.90 | 2019-2023 | Mavyret |
| Merck Sharp & Dohme LLC | $55.10 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $39.95 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.83 | 2019-2023 | Entyvio |
| Olympus America INC. | $32.04 | 2025 | Visiglide, Hanarostent Esophagus Tts(Ccc) |
| Celltrion USA INC. | $32.00 | 2025 | Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $25.47 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.01 | 2023 | Cologuard Collection Kit |
| Apollo Endosurgery US INC | $17.34 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.15 | 2024 | Voquezna |
| Lilly USA, LLC | $15.79 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $15.52 | 2023 | Lockado |
| Shire North American Group INC | $13.62 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.33 | 2023 | Ocaliva |
| Medtronic, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Stowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.